EMD 57445: A selective sigma receptor ligand with the profile of an atypical neuroleptic

CNS Drug Reviews

Volumn 2, Issue 2, 1996, Pages 175-194

  Bartoszyk, G D ^a   Bender, H M ^b   Hellmann, J ^a   Schnorr, C ^a   Seyfried, C A ^a  

^a MERCK KGAA   (Germany)

^b Inst for Pharmacokin and Metab   (Germany)

Author keywords

Atypical Neuroleptic; Clozapine; Dopamine antagonist; EMD 57445; Haloperidol; Panamesine; Schizophrenia; Sigma ligand

Indexed keywords

DOPAMINE RECEPTOR BLOCKING AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; PANAMESINE; SIGMA OPIATE RECEPTOR; UNCLASSIFIED DRUG;

DRUG RECEPTOR BINDING; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LIGAND BINDING; RECEPTOR BINDING; REVIEW; SCHIZOPHRENIA;

EID: 0030017532     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.1996.tb00296.x     Document Type: Review

References (44)

1. Altar CA, Boyar WC, Wasley A, Gerhardt SC, Liebman JM, Wood PL. Dopamine neurochemical profile of atypical antipsychotics resemble that of D-1 antagonists. Naunyn-Schmiedeberg's Arch Pharmacol 1988;338:162-168.
2. Amt J, Hyttel J, Meier E. Inactivation of dopamine D-1 or D-2 receptors differentially inhibits stereotypies by dopamine agonists in rats. Eur J Pharmacol 1988;155:37-47.
3. Bartoszyk GD, Bender HM, Heusener A, Schnorr C. Pharmacology of the potential antipsychotic EMD 57445 in animals and humans. Eur Neuropsychopharmacol 1995;5:331.
4. Bartoszyk GD, Greiner HE, Harting J, Stohrer M, Seyfried CA. Pharmacological profile of the atypical neuroleptic drug EMD 57445. Soc Neurosci Abstr 1992;18:548.
5. Bastianetto S, Rouquier L, Perrault G, Sanger DJ. DTG-induced circling behaviour in rats may involve the interaction between σ sites and nigro-striatal dopaminergic pathways. Neuropharmacology 1995;34: 281-287.
6. Carlsson A, Svensson A, Carlsson ML. Future strategies in the discovery of new antipsychotic agents: Focus on dopamine-glutamate interactions. Int Acad Biomed Drug Res 1993;4:118-129.
7. 10 mesolimbic system by the σ-receptor agonist (+)SKF 10,047 can be blocked by rimcazole, a novel putative antipsychotic. Eur J Pharmacol 1988;154:53-57.
8. Chouinard G, Annable L. An early Phase II clinical trail of BW234U in the treatment of acute schizophrenia in newly admitted patients. Psychopharmacology 1984;84:282-284.
9. Clissold DB, Pontecorvo MJ, Jones BE, et al. NPC 16377, a potent and selective σ-ligand. II. Behavioral and neuroprotective profile. J Pharmacol Exp Ther 1993;265:876-886.
10. Dahmen N, Fischer V, Hödl P, Rujescu D, Reuss S, Hiemke C. Induction of c-fos gene expression by the selective sigma receptor ligand EMD 57445 in rat brain. Naunyn-Schmiedeberg's Arch Pharmacol (Suppl) 1995;351:R 162.
11. Davidson J, Miller R, Wingfield M, Zung W, Dren AT. The first clinical study of BW-234U in schizophrenia. Psychopharmacol Bull 1982;18:173-176.
12. Debonnel G. Current hypotheses on sigma receptors and their physiological role: Possible implications in psychiatry. J Psychiatr Neurosci 1993;18:157-172.
13. Deutch AY, Moghaddam B, Innis RB, et al. Mechanisms of action of atypical antipsychotic drugs: Implications for novel therapeutic strategies for schizophrenia. Schizophrenia Res 1991;4:121-156.
14. Deutch AY, Tam SW, Freeman AS, Bowers MB, Rotha RH Jr. Mesolimbic and mesocortical dopamine activation induced by phencyclidine: Contrasting pattern to striatal response. Eur J Pharmacol 1987;134: 257-264.
15. Deutsch SI, Weizman A, Goldman ME, Morihisa JM. The sigma receptor: A novel site implicated in psychosis and antipsychotic drug efficacy. Clin Neuropharmacol 1988;11:105-119.
16. Ferris RM, Harfenist M, McKenzie GM, Cooper B, Soroko FE, Maxwell RA. BW 234U, (cis-9-[3,5-dimethyl-1-piperazinyl)propyl]carbazole dihydrochloride): A novel antipsychotic agent. J Pharm Pharmacol 1982;34:388-390.
17. Ferris RM, Tang FLM, Chang K-J. Evidence that the potential antipsychotic agent rimcazole (BW 234U) is a specific, competitive antagonist of sigma sites in brain. Life Sci 1986;38:2329-2337.
18. Fink-Jensen A, Kristensen P. Effects of typical and atypical neuroleptics on Fos expression in the rat forebrain. Neurosci Lett 1994;182:115-118.
19. Freeman AS, Bunney BS. The effects of phencyclidine and N-allylnormetazocine on midbrain dopamine neuronal activity. Eur J Pharmacol 1984;104:287-293.
20. Haertzen CA. Subjective effects of narcotic antagonists cyclazocine and nalorphine on the addiction research center inventory (ARCI). Psychopharmacologia 1970;18:366-377.
21. Irwin S. Comprehensive observational assessment: A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse. Psychopharmacologia 1968;13:222-257.
22. Karbon EW, Abreu ME, Erickson RH, et al. NPC 16377, a potent and selective σ-ligand. I. receptor binding, neurochemical and neuroendocrine profile. J Pharmacol Exp Ther 1993;265:866-875.
23. Klavans HL, Carvey PM, Nelson D, Tanner CM, Goetz CG. The effect of thioridazine and haloperidol induced behavioral hypersensitivity. Life Sci 1986;38:1707-1714.
24. Lang A, Vasar E, Soosaar A, Harro J. The involvement of sigma and phencyclidine receptors in the action of antipsychotic drugs. Pharmacol Toxicol 1992;71:132-138.
25. Largent BL, Wikström H, Snowman AM, Snyder SH. Novel antipsychotic drugs share high affinity for σ receptors. Eur J Pharmacol 1988;155:345-347.
26. Lieberman JA. Understanding the mechanism of action of atypical antipsychotic drugs. A review of compounds in use and development. Brit J Psychiatry (Suppl 22) 1993;163:7-18.
27. MacGibbon GA, Lawlor PA, Bravo R, Dragunow M. Clozapine and haloperidol produce a differential pattern of immediate early gene expression in rat caudate-putamen, nucleus accumbens, lateral septum, and island of Calleja. Mol Brain Res 1994;23:21-32.
28. Matsuno K, Matsunaga KH, Mita S. Acute effects of sigma ligands on the extracellular DOPAC level in rat frontal cortex and striatum. Neurochem Res 1995;20:233-238.
29. May J, Skuza G, Rogóz Z. Central effects of EMD 57445, a new sigma receptor ligand with a potential antipsychotic activity. Eur Neuropsychopharmacol 1995;5:327.
30. Nguyen TV, Kosofsky BE, Birnbaum R, Cohen BM, Hyman SE. Differential expression of c-Fos and Zif268 in rat striatum after haloperidol, clozapine, and amphetamine. Proc Natl Acad Sci USA 1992;89: 4270-4274.
31. Niemegeers CJE, Janssen PAJ. A systematic study of the pharmacological activities of dopamine antagonists. Life Sci 1979;24:2201-2216.
32. Niemegeers CJE, Verbruggen FJ, Janssen PAJ. The influence of various neuroleptic drugs on shock avoidance responding in rats. Psychopharmacology 1969;16:161-174.
33. Poncelet M, Santucci V, Paul R, et al. Neuropharmacological profile of a novel and selective ligand of the sigma site: SR 31742A. Neuropharmacology 1993;32:605-615.
34. Prücher H, Gottschlich R, Haase A, Stohrer M, Seyfried C. (5S)-3-aryl-5-(1-piperidinylmethyl)-2-oxazolidinones, a new class of potential neuroleptics with affinity for the sigma receptor. Bioorg Med Chem Lett 1992;2:165-170.
35. Robertson GS, Fibiger HC. Neuroleptics increase c-fos expression in the forebrain: Contrasting effects of haloperidol and clozapine. Neuroscience 1992;46:315-328.
36. 2-autoreceptor agonists, with special reference to indolybutylamines. Drugs of the Future 1990;15:819-832.
37. Shibuya H, Mori H, Toru M. Sigma receptors in schizophrenic cerebral cortices. Neurochem Res 1992;17: 983-990.
38. Simpson MDC, Slater P, Royston MC, Deakin JFW. Alterations in phencyclidine and sigma binding sites in schizophrenic brains: Effects of disease process and neuroleptic medication. Schizophrenia Res 1992;6: 41-48.
39. Taylor DP, Dekleva J. Potential antipsychotic BMY 14802 selectively binds to sigma sites. Drug Dev Res 1987;11:65-70.
40. Ungerstedt U, Arbuthnott GW. Quantitative recording of rotational behavior in rats after 6-hydroxydopamine lesions of the nigrostriatal dopamine system. Brain Res 1970;24:485-493.
41. Wachtel SR, White FJ. Electrophysiological effects of BMY 14802, a new potential antipsychotic drug, on midbrain dopamine neurons in the rat: Acute and chronic studies. J Pharmacol Exp Ther 1988;244: 410-416.
42. Walker JM, Bowen WD, Walker FO, Matsumoto RR, De Costa B, Rice KC. Sigma receptors: Biology and function. Pharmacol Rev 1990;42:355-402.
43. 3H]propyl-2-aminotetralin and carbetapentane. J Neurochem 1995;64: 700-710.
44. Weissmann AD, Casanova MF, Kleinmann JE, London ED, De Souza EB. Selective loss of cerebral cortical sigma, but not PCP binding sites in schizophrenia. Biol Psychiatry 1991;29:41-54.